- Home
- AZ vs ARCT Comparison
AZ vs ARCT Comparison
Compare AZ & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZ
- ARCT
- Stock Information
- Founded
- AZ 2018
- ARCT 2013
- Country
- AZ Canada
- ARCT United States
- Employees
- AZ N/A
- ARCT N/A
- Industry
- AZ Industrial Machinery/Components
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- AZ Industrials
- ARCT Health Care
- Exchange
- AZ Nasdaq
- ARCT Nasdaq
- Market Cap
- AZ 270.4M
- ARCT 298.3M
- IPO Year
- AZ N/A
- ARCT N/A
- Fundamental
- Price
- AZ $9.28
- ARCT $12.81
- Analyst Decision
- AZ Strong Buy
- ARCT Strong Buy
- Analyst Count
- AZ 1
- ARCT 8
- Target Price
- AZ $20.00
- ARCT $52.33
- AVG Volume (30 Days)
- AZ 196.4K
- ARCT 464.1K
- Earning Date
- AZ 05-15-2025
- ARCT 05-12-2025
- Dividend Yield
- AZ N/A
- ARCT N/A
- EPS Growth
- AZ N/A
- ARCT N/A
- EPS
- AZ N/A
- ARCT N/A
- Revenue
- AZ $7,443,000.00
- ARCT $143,680,000.00
- Revenue This Year
- AZ $1,343,857.60
- ARCT N/A
- Revenue Next Year
- AZ N/A
- ARCT $42.36
- P/E Ratio
- AZ N/A
- ARCT N/A
- Revenue Growth
- AZ N/A
- ARCT 15.38
- 52 Week Low
- AZ $0.85
- ARCT $8.04
- 52 Week High
- AZ $9.93
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- AZ 59.12
- ARCT 56.34
- Support Level
- AZ $8.55
- ARCT $11.51
- Resistance Level
- AZ $9.84
- ARCT $13.00
- Average True Range (ATR)
- AZ 0.82
- ARCT 1.01
- MACD
- AZ -0.01
- ARCT 0.09
- Stochastic Oscillator
- AZ 60.12
- ARCT 66.07
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.